



微量氯胺酮对晚期癌痛患者自控静脉镇痛的优化作用

李金玉, 郑国龙, 胡伟

223300 江苏淮安, 南京医科大学附属淮安市第一医院麻醉科

Micro-dose Ketamine on Optimized Patient-controlled Intravenous Analgesia in Advanced Cancer Patients

LI Jin-yu, ZHENG Guo-long, HU Wei

Department of Anesthesiology, The 1st Hospital of Huai an, Affiliated Hospital of Nanjing Medical University, Huai an 223300, China

- 摘要
- 参考文献
- 相关文章

全文: PDF (481 KB) HTML (0 KB) 输出: BibTeX | EndNote (RIS) 背景资料

摘要 目的研究微量氯胺酮配伍芬太尼在晚期癌痛患者, 自控静脉镇痛(PCIA)中应用的效应及安全性。方法80例需镇痛的晚期癌痛患者随机分为芬太尼组(F组)(n=20)和芬太尼氯胺酮复合组(FK组)(n=60), FK组包括人数相等的三组, 即FK1组(n=20)、FK2组(n=20)和FK3组(n=20) 三组。各组患者镇痛液中都含有芬太尼100 μg/ml。FK1组、FK2组和FK3组三组患者镇痛液中分别另含有氯胺酮1 mg/ml、2 mg/ml和3 mg/ml; 观察和记录镇痛过程中: 镇痛评分、镇静评分、芬太尼消耗量、呼吸抑制、谵妄等并发症。结果在无负荷情况下, 达到相同镇痛状态用时, FK2、FK3组比F组和FK1组的快一倍。在镇痛过程中, F组芬太尼消耗量呈现明显递增态势, 和镇痛初期比较后期消耗量显著增加; FK组芬太尼消耗量总体前后恒定。镇痛后期F组芬太尼消耗量显著多于FK组。FK组中FK2组患者镇痛效果更佳, 维持过程中患者几乎不用操控镇痛泵。FK3组患者芬太尼消耗量较其他三组患者显著减少, 患者过度镇静发生率显著增加。所有患者没有出现呼吸抑制、幻觉、谵妄等症状。结论微量氯胺酮通过抗痛觉过敏和对阿片受体耐受的保护, 能够显著减少芬太尼消耗量, 有效保护芬太尼耐受, 提升晚期癌痛患者芬太尼PCIA镇痛品质。在芬太尼每分钟0.006 μg/kg左右输注量下, 匹配氯胺酮每分钟(1.3 ±0.02) μg/kg输注量是较为理想的组合。

关键词: 氯胺酮 芬太尼 PCIA 癌痛

Abstract: Objective Our study was to analyze the effect and safety of micro-dose ketamine plus fentanyl in patient-controlled intravenous analgesia (PCIA) for advanced cancer. Methods Eighty advanced cancer pain patients required were randomly divided into fentanyl group (group F) (n=20) and ketamine plus fentanyl groups (FK) (n=60). FK group included three groups of equal number, ie. FK1 Group(100 μg/ml fentanyl+ 1 mg/ml ketamine), FK2 Group(100 μg/ml fentanyl+ 2 mg/ml ketamine) and FK3 Group(100 μg/ml fentanyl+ 3 mg/ml ketamine). Analgesic consumption score, sedation score, respiratory depression, delirium and other complications were recorded during analgesia. Results In non-load condition, the onset time of analgesia in group FK2, FK3 was shorter than that in group F and group FK1. Fentanyl consumption in group F showed obviously increasing trend. Fentanyl consumption in group FK was constant during treatment and lower than that in group F. Group FK2 patients had better effect, almost did not need to regulate analgesia pump. Fentanyl consumption in FK3 was significant lower than that in other three groups, although with increased incidence of excessive sedation. No respiratory depression, hallucinations, delirium and other symptoms were observed. Conclusion Micro-dose ketamine could significantly reduce fentanyl consumption through protection of anti-opioid receptor, improve fentanyl tolerance, and enhance the quality of fentanyl PCIA analgesia in patients with advanced cancer. 0.006 μg/kg. fentanyl plus (1.3 ±0.02) μg/kg ketamine was an ideal combination.

Key words: Ketamine Fentanyl PCIA Cancer pain

收稿日期: 2011-03-03;

服务

把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS

作者相关文章

李金玉
郑国龙
胡伟

没有本文参考文献

- [1] 赵迎超;程晶;张盛;董晓荣;黄方;姜瑶. 阿扎司琼注射液预防芬太尼透皮贴剂所致的肿瘤患者恶心呕吐的疗效观察 [J]. 肿瘤防治研究, 2012, 39(2): 210-212.
- [2] 严鹏;陈元. 泰勒宁对比美施康定治疗中重度癌痛的疗效评价 [J]. 肿瘤防治研究, 2011, 38(3): 324-325.
- [3] 朱定成;钟爱军;沈怡;武潜;殷刚;蹇新民;吴谦;李英. 罗哌卡因复合芬太尼用于乳腺癌术后硬膜外自控镇痛的临床观察[J]. 肿瘤防治研究, 2011, 38(1): 87-89.
- [4] 黄培强;冯刚;张丽娟. 吗啡缓释片直肠、口服给药方式在癌痛治疗中的疗效比较[J]. 肿瘤防治研究, 2008, 35(S1): 26-26,27.
- [5] 朱定成;袁世炎. 乳腺癌根治术后芬太尼、曲马多与吗啡病人自控镇痛的比较[J]. 肿瘤防治研究, 2008, 35(1): 55-57.
- [6] 陈元香;尼莫地平、辛伐他汀联合吗啡控释片治疗癌痛71例疗效分析[J]. 肿瘤防治研究, 2007, 34(10): 792-792,797.
- [7] 周清;王坤;杨衿记;张华;黄玉娟;廖日强;吴一龙. 芬太尼透皮贴剂联合高剂量帕米膦酸二钠治疗多发性骨转移疼痛的疗效及耐受性观察 [J]. 肿瘤防治研究, 2006, 33(10): 760-762.
- [8] 刘义树;蔡志;杜嘉陵;余鸣. 芬太尼与曲马多在晚期癌性镇痛中的应用[J]. 肿瘤防治研究, 2005, 32(6): 385-386.
- [9] 丁健;庄建生;林新民;胡冰;季楚舒;胡长路;江丰收;徐腾云;陈曼萍;何义富;孙玉蓓. 多瑞吉治疗42例中、重度晚期癌痛 [J]. 肿瘤防治研究, 2003, 30(5): 411-412.
- [10] 薛亚军;蹇新民;余鸣;黄志松;曾辉. 芬太尼与曲马多联合自控静脉镇痛用于肺癌根治术后的观察[J]. 肿瘤防治研究, 2003, 30(2): 154-155.
- [11] 胡宏年. 岩舒注射液治疗IV期非小细胞肺癌的临床疗效观察[J]. 肿瘤防治研究, 2001, 28(5): 392-393.